<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053183</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269300</org_study_id>
    <secondary_id>NABTT-2105</secondary_id>
    <secondary_id>JHOC-NABTT-2105</secondary_id>
    <nct_id>NCT00053183</nct_id>
  </id_info>
  <brief_title>Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>Phase I Brachytherapy Dose Escalation Using The GliaSite RTS In Newly Diagnosed Glioblastoma Multiforme In Conjunction With External Beam Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor&#xD;
      to kill tumor cells. External-beam radiation therapy uses high-energy x-rays to kill tumor&#xD;
      cells. Combining internal radiation with external-beam radiation therapy may kill any&#xD;
      remaining tumor cells following surgery.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining internal radiation therapy&#xD;
      with external-beam radiation therapy in treating patients who have undergone surgery for&#xD;
      glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of brachytherapy administered via GliaSite RTS™&#xD;
           applicator followed by external beam radiotherapy in patients with newly diagnosed&#xD;
           glioblastoma multiforme.&#xD;
&#xD;
        -  Determine the acute and chronic toxicity of brachytherapy administered via GliaSite RTS™&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the survival rate of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of brachytherapy.&#xD;
&#xD;
      Patients undergo craniotomy for histologic confirmation of glioblastoma multiforme, surgical&#xD;
      resection, and placement of a GliaSite RTS™ applicator that includes Iotrex™.&#xD;
&#xD;
      Beginning 3-21 days after surgery, patients undergo brachytherapy via the GliaSite RTS™&#xD;
      applicator. Within 30 days of brachytherapy (no more than 60 days after resection) patients&#xD;
      undergo external beam radiotherapy 5 days a week for 6 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 5-10 patients receive escalating doses of brachytherapy until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at&#xD;
      least 2 of 5 or 3 of 10 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 21-35 days, every 2 months for 1 year, and then for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinically suspected supratentorial grade IV glioblastoma multiforme&#xD;
&#xD;
          -  Candidate for maximal surgical resection of tumor mass&#xD;
&#xD;
               -  Expected residual enhancing tumor must be within the expected brachytherapy&#xD;
                  treatment volume&#xD;
&#xD;
               -  Resection must not be expected to result in a new permanent neurologic deficit&#xD;
&#xD;
          -  No clearly multi-focal disease (2 or more separate foci of contrast-enhancing tumor&#xD;
             not all within the expected brachytherapy prescription volume by MRI)&#xD;
&#xD;
          -  No enhancing tumor greater than 1 cm beyond the midline by MRI&#xD;
&#xD;
          -  No grossly or radiographically apparent leptomeningeal spread and/or ventricular&#xD;
             invasion outside the anticipated radiation treatment volume&#xD;
&#xD;
          -  No marked edema by MRI with significant shift that is not anticipated to be corrected&#xD;
             by resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.7 mg/dL&#xD;
&#xD;
          -  BUN no greater than 2 times upper limit of normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac dysrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Mini mental state exam score at least 15&#xD;
&#xD;
          -  No other concurrent medical illness that would preclude study participation&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No immunotherapy prior to, during, or within 90 days after brachytherapy&#xD;
&#xD;
          -  No biologic therapy with any of the following prior to, during, or within 90 days&#xD;
             after brachytherapy :&#xD;
&#xD;
               -  Immunotoxins&#xD;
&#xD;
               -  Immunoconjugates&#xD;
&#xD;
               -  Antiangiogenesis compounds&#xD;
&#xD;
               -  Peptide receptor antagonists&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Interleukins&#xD;
&#xD;
               -  Tumor-infiltrating lymphocytes&#xD;
&#xD;
               -  Lymphokine-activated killer cells&#xD;
&#xD;
               -  Gene therapy&#xD;
&#xD;
               -  Antisense agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No chemotherapy or polifeprosan 20 with carmustine implant (Gliadel wafers) prior to,&#xD;
             during, or within 90 days after brachytherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No hormonal therapy prior to, during, or within 90 days after brachytherapy&#xD;
&#xD;
          -  Concurrent corticosteroids to improve quality of life allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No other radiotherapy prior to, during, or within 90 days after brachytherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No radiosurgery prior to, during, or within 90 days after brachytherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other investigational agents directed at the brain tumor prior to, during, or&#xD;
             within 90 days after brachytherapy&#xD;
&#xD;
          -  Concurrent noncytotoxic therapy to improve quality of life allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker W. Stieber, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

